FDA 483 - KBI Biopharma, Inc. - April 01, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
KBI Biopharma Inc. in Durham, NC, a drug substance manufacturer, received an FDA Form 483 citing significant quality system deficiencies. Observations included inadequate environmental controls in ISO 5 areas, failure to follow validated monitoring procedures, and insufficient investigation and documentation of invalid assay results. The firm also failed to maintain proper chain of custody for samples, adequately address deviations with effective CAPAs, and perform required annual product quality reviews.
ID · e8056555-57db-48c7-82f7-bc168dca579c